AbCellera

Last updated

AbCellera Biologics Inc.
Type Public
Nasdaq:  ABCL
Industry Biotechnology
Founded2012;11 years ago (2012)
Headquarters Vancouver, British Columbia
Revenue375.2 million (2021)
Number of employees
386 (2021)
Website www.abcellera.com   OOjs UI icon edit-ltr-progressive.svg

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. [1] AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." [2] Its platform for single-cell screening was initially developed at the University of British Columbia. [3]

Contents

History

AbCellera was founded in 2012 by biomedical researchers Carl Hansen, Véronique Lecault, Kevin Heyries, Daniel Da Costa and Oleh Petriv. In November 2016, the company received a US$645K grant from the Bill & Melinda Gates Foundation to develop a test for tuberculosis. [4] In September 2018, a $10M series A round of funding was closed. [5] In May 2020, a $105M series B round of funding was closed. [6] [7]

In January 2017, AbCellera announced that it would be collaborating with Pfizer to discover and develop antibodies against "undisclosed membrane protein targets.” [8] [9]

COVID-19 and expansion

In June 2020, AbCellera announced it had begun the world's first study of a potential antibody treatment against COVID-19, with a Phase 1 trial of LY-CoV555 (Bamlanivimab), in collaboration with Eli Lilly and Company. [10] The drug was granted an Emergency Use Authorization by the U.S. Food and Drug Administration in November 2020, and subsequently renewed in February and March 2021. [11] [12] The EUA was revoked in April 2021, with the FDA citing an updated conclusion that "the known and potential benefits of bamlanivimab alone no longer outweigh the known and potential risks for the product," because of significantly reduced efficacy against emerging variants of SARS-CoV-2. [13] In November 2020, Peter Thiel joined AbCellera's board of directors and disclosed a 5.3% stake in the company. [14] [15]

In September 2021, the company announced a multi-year agreement with Moderna to develop mRNA-based antibody treatments against multiple diseases. [16]

In January 2022, the company received a $1.5 million grant from the Bill & Melinda Gates Foundation to identify monoclonal antibodies against respiratory syncytial virus (RSV). [17] A second COVID-19 monoclonal antibody therapy (Bebtelovimab) was given Emergency Use Authorization in February 2022, with the U.S. Government committing to a $720 million purchase of up to 600,000 doses. [18]

Other partnerships include collaborations with Ablynx, Gilead Sciences, GlaxoSmithKline, Merck, Novartis, Sanofi and Teva Pharmaceutical Industries. [19] [20]

See also

Related Research Articles

<span class="mw-page-title-main">Monoclonal antibody</span> Antibodies from clones of the same blood cell

A monoclonal antibody is an antibody produced from a cell lineage made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell.

<span class="mw-page-title-main">Eli Lilly and Company</span> American pharmaceutical company

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War.

In immunology, antiserum is a blood serum containing antibodies that is used to spread passive immunity to many diseases via blood donation (plasmapheresis). For example, convalescent serum, passive antibody transfusion from a previous human survivor, used to be the only known effective treatment for ebola infection with a high success rate of 7 out of 8 patients surviving.

<span class="mw-page-title-main">Regeneron Pharmaceuticals</span> American biotechnology company

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

MorphoSys AG is a biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany and has a wholly owned subsidiary, MorphoSys US Inc., in Boston MA in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.

An Emergency Use Authorization (EUA) in the United States is an authorization granted to the Food and Drug Administration (FDA) under sections of the Federal Food, Drug, and Cosmetic Act as added to and amended by various Acts of Congress, including by the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA), as codified by 21 U.S.C. § 360bbb-3, to allow the use of a drug prior to approval. It does not constitute approval of the drug in the full statutory meaning of the term, but instead authorizes the FDA to facilitate availability of an unapproved product, or an unapproved use of an approved product, during a declared state of emergency from one of several agencies or of a "material threat" by the Secretary of Homeland Security.

<span class="mw-page-title-main">Novavax</span> American biotechnology company

<span class="mw-page-title-main">COVID-19 drug development</span> Preventative and therapeutic medications for COVID-19 infection

COVID-19 drug development is the research process to develop preventative therapeutic prescription drugs that would alleviate the severity of coronavirus disease 2019 (COVID-19). From early 2020 through 2021, several hundred drug companies, biotechnology firms, university research groups, and health organizations were developing therapeutic candidates for COVID-19 disease in various stages of preclinical or clinical research, with 419 potential COVID-19 drugs in clinical trials, as of April 2021.

Jason S. McLellan is a structural biologist, professor in the Department of Molecular Biosciences and Robert A. Welch Chair in Chemistry at The University of Texas at Austin who specializes in understanding the structure and function of viral proteins, including those of coronaviruses. His research focuses on applying structural information to the rational design of vaccines and other therapies for viruses, including SARS-CoV-2, the novel coronavirus that causes COVID-19, and respiratory syncytial virus (RSV). McLellan and his team collaborated with researchers at the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center to design a stabilized version of the SARS-CoV-2 spike protein, which biotechnology company Moderna used as the basis for the vaccine mRNA-1273, the first COVID-19 vaccine candidate to enter phase I clinical trials in the U.S. At least three other vaccines use this modified spike protein: those from Pfizer and BioNTech; Johnson & Johnson and Janssen Pharmaceuticals; and Novavax.

Although several medications have been approved in different countries as of April 2022, not all countries have these medications. Patients with mild to moderate symptoms who are in the risk groups can take nirmatrelvir/ritonavir or remdesivir, either of which reduces the risk of serious illness or hospitalization. In the US, the Biden Administration COVID-19 action plan includes the Test to Treat initiative, where people can go to a pharmacy, take a COVID test, and immediately receive free Paxlovid if they test positive.

<span class="mw-page-title-main">BioNTech</span> German biotechnology company

BioNTech SE is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer.

<span class="mw-page-title-main">Casirivimab/imdevimab</span> Antiviral combination medication

Casirivimab/imdevimab, sold under the brand name REGEN‑COV among others, is a combination medicine used for the treatment and prevention of COVID‑19. It consists of two human monoclonal antibodies, casirivimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. It is also available as a co-formulated product. It was developed by the American biotechnology company Regeneron Pharmaceuticals.

<span class="mw-page-title-main">Pfizer–BioNTech COVID-19 vaccine</span> Type of vaccine for humans

The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with American company Pfizer to carry out clinical trials, logistics, and manufacturing. It is authorized for use in people to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus. The vaccine is given by intramuscular injection. It is composed of nucleoside-modified mRNA (modRNA) encoding a mutated form of the full-length spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles. Initial advice indicated that vaccination required two doses given 21 days apart, but the interval was later extended to up to 42 days in the US, and up to four months in Canada.

Bamlanivimab is a monoclonal antibody developed by AbCellera Biologics and Eli Lilly as a treatment for COVID-19. The medication was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in November 2020, and the EUA was revoked in April 2021.

Bamlanivimab/etesevimab is a combination of two monoclonal antibodies, bamlanivimab and etesevimab, administered together via intravenous infusion as a treatment for COVID-19. Both types of antibody target the surface spike protein of SARS‑CoV‑2.

<span class="mw-page-title-main">Sotrovimab</span> Monoclonal antibody

Sotrovimab, sold under the brand name Xevudy, is a human neutralizing monoclonal antibody with activity against severe acute respiratory syndrome coronavirus 2, known as SARS-CoV-2. It was developed by GlaxoSmithKline and Vir Biotechnology, Inc. Sotrovimab is designed to attach to the spike protein of SARS-CoV-2.

<span class="mw-page-title-main">Tixagevimab/cilgavimab</span> Monoclonal antibody treatment for COVID-19

Tixagevimab/cilgavimab, sold under the brand name Evusheld, is a combination of two human monoclonal antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061) targeted against the surface spike protein of SARS-CoV-2 used to prevent COVID-19. It is being developed by British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca. It is co-packaged and given as two separate consecutive intramuscular injections.

<span class="mw-page-title-main">John R. Mascola</span> American Physician-Scientist

John R. Mascola is an American physician-scientist, immunologist and infectious disease specialist. He was the director of the Vaccine Research Center (VRC), part of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). He also served as a principal advisor to Anthony Fauci, director of NIAID, on vaccines and biomedical research affairs. Mascola is the current Chief Scientific Officer for ModeX Therapeutics.

<span class="mw-page-title-main">Nirmatrelvir/ritonavir</span> Antiviral combination medication

Nirmatrelvir/ritonavir, sold under the brand name Paxlovid, is a co-packaged medication used as a treatment for COVID‑19. It contains the antiviral medications nirmatrelvir and ritonavir and was developed by Pfizer. Both are protease inhibitors: nirmatrelvir inhibits SARS-CoV-2 main protease, while ritonavir inhibits HIV-1 protease, and is additionally a strong CYP3A inhibitor.

Bebtelovimab is a monoclonal antibody developed by AbCellera and Eli Lilly as a treatment for COVID-19.

References

  1. ↑ Niiler, Eric (2020-02-14). "Darpa Cranks Up Antibody Research to Stall Coronavirus". Wired . Condé Nast . Retrieved 2020-02-16.
  2. ↑ Cumbers, John (2020-02-05). "The Synthetic Biology Companies Racing To Fight Coronavirus". Forbes . Retrieved 2020-02-16.
  3. ↑ Shore, Randy (2017-03-03). "B.C.'s biotech leaders are growing up and going global". Vancouver Sun . Postmedia Network . Retrieved 2020-02-16.
  4. ↑ "Grant: AbCellera Biologics Inc". Bill & Melinda Gates Foundation . November 2016. Archived from the original on 2022-05-04. Retrieved 2020-02-16.
  5. ↑ McGrane, Clare (2018-09-27). "AbCellera raises $10M for machine-learning fueled antibody discovery platform". GeekWire . Retrieved 2020-02-16.
  6. ↑ Gormley, Brian (2020-05-27). "AbCellera Banks $105 Million for Antibodies, Including for Covid-19". Wall Street Journal. ISSN   0099-9660 . Retrieved 2020-07-21.
  7. ↑ Knapp, Alex. "AbCellera Raises $105 Million To Boost Drug Discovery Against Coronavirus And Other Diseases". Forbes. Retrieved 2020-07-21.
  8. ↑ Heyries, Kevin (2017-01-05). "AbCellera Announces Multi-Target Research Collaboration with Pfizer". AbCellera. Archived from the original on 2022-05-04. Retrieved 2022-05-04.
  9. ↑ "Research programme: transmembrane protein modulators - AbCellera/Pfizer". Adis Insight - Springer Science+Business Media . 2021-02-28. Archived from the original on 2022-05-04. Retrieved 2022-05-04.
  10. ↑ "Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans". Lilly. 1 June 2020. Retrieved 4 June 2020.
  11. ↑ "An EUA for Bamlanivimab—A Monoclonal Antibody for COVID-19". JAMA. 325 (9): 880–881. 2021-03-02. doi: 10.1001/jama.2020.24415 . ISSN   0098-7484. PMID   33306087.
  12. ↑ Hinton, Denise M. (2021-04-16). "RE: Emergency Use Authorization 090". U.S. Food & Drug Administration . Archived from the original on 2022-04-06. Retrieved 2022-05-04.
  13. ↑ Office of the Commissioner (2021-04-19). "Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab". U.S. Food & Drug Administration . Archived from the original on 2021-05-27. Retrieved 2022-05-04.
  14. ↑ Mayani, Mamta (2020-12-29). "Peter Thiel reports 5.3% stake in AbCellera Bio (NASDAQ:ABCL)". Seeking Alpha. Archived from the original on 2022-05-04. Retrieved 2022-05-04.
  15. ↑ Yingling, Jessica (2020-11-19). "Peter Thiel Joins AbCellera's Board of Directors". AbCellera. Archived from the original on 2022-05-04. Retrieved 2022-05-04.
  16. ↑ Khandekar, Amruta (2021-09-15). "AbCellera and Moderna team up to develop antibody therapies". Reuters . Retrieved 2022-05-04.
  17. ↑ "AbCellera Biologics Inc". Bill & Melinda Gates Foundation . January 2022. Archived from the original on 2022-05-04. Retrieved 2022-05-04.
  18. ↑ Tong, Amber (2022-02-14). "As Omicron rages, FDA clears Eli Lilly/AbCellera's new antibody days after $720M supply deal". Endpoints News. Archived from the original on 2022-02-15. Retrieved 2022-05-04.
  19. ↑ "AbCellera collaborates with Novartis for antibody discovery". PharmaTimes. 2019-02-14. Retrieved 2020-02-16.
  20. ↑ "Partnership". AbCellera. Archived from the original on 2022-05-04. Retrieved 2022-05-04.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.